Stock Analysis

Additional Considerations Required While Assessing Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd's (SHSE:603227) Strong Earnings

SHSE:603227
Source: Shutterstock

Xinjiang Xuefeng Sci-Tech(Group)Co.,Ltd (SHSE:603227) announced strong profits, but the stock was stagnant. Our analysis suggests that this might be because shareholders have noticed some concerning underlying factors.

View our latest analysis for Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd

earnings-and-revenue-history
SHSE:603227 Earnings and Revenue History April 17th 2024

To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. In fact, Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd increased the number of shares on issue by 11% over the last twelve months by issuing new shares. Therefore, each share now receives a smaller portion of profit. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd's historical EPS growth by clicking on this link.

A Look At The Impact Of Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd's Dilution On Its Earnings Per Share (EPS)

Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd has improved its profit over the last three years, with an annualized gain of 694% in that time. In comparison, earnings per share only gained 401% over the same period. And at a glance the 28% gain in profit over the last year impresses. Meanwhile, EPS was flat over the same period. So you can see that the dilution has had a bit of an impact on shareholders.

Changes in the share price do tend to reflect changes in earnings per share, in the long run. So it will certainly be a positive for shareholders if Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd can grow EPS persistently. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd's Profit Performance

Each Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd share now gets a meaningfully smaller slice of its overall profit, due to dilution of existing shareholders. Because of this, we think that it may be that Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd's statutory profits are better than its underlying earnings power. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you'd like to know more about Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd as a business, it's important to be aware of any risks it's facing. You'd be interested to know, that we found 2 warning signs for Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd and you'll want to know about them.

This note has only looked at a single factor that sheds light on the nature of Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Valuation is complex, but we're helping make it simple.

Find out whether Xinjiang Xuefeng Sci-Tech(Group)Co.Ltd is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.